Completed PHASE4 INTERVENTIONAL 2-arm NCT04585737

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF (DYAD)

Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine in Virologically-suppressed Adults Living With HIV on Bictegravir/Tenofovir Alafenamide/emtricitabine-the DYAD Study

Sponsor: Charlotte-Paige Rolle, MD

Conditions HIV I Infection

Interventions Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill Dolutegravir / Lamivudine Pill

Updated 7 times since 2020 Last updated: Sep 24, 2024 Started: Oct 5, 2020 Primary completion: Aug 3, 2023 Completion: Aug 10, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates HIV I Infection and is currently completed. Charlotte-Paige Rolle, MD leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Nov 2024 — Present [monthly]

Completed PHASE4
Sep 2024 — Nov 2024 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2023 — Jul 2024 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Sep 2022 — Dec 2023 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Jan 2021 — Sep 2022 [monthly]

Recruiting PHASE4
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charlotte-Paige Rolle, MD
ViiV Healthcare

Data source: Orlando Immunology Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orlando, United States